Grape seed proanthocyanidins are known to possess a broad spectrum of pharm
acological, medicinal and therapeutic properties. Previous studies in our l
aboratories have demonstrated the various protective abilities of a novel I
H636 grape seed proanthocyanidin extract (GSPE) against various pathologic
conditions. However no extensive safety studies have been conducted on grap
e seed proanthocyanidins to date. This study demonstrates the acute and chr
onic safety studies on GSPE. Acute oral toxicity, dermal toxicity, dermal i
rritation and eye irritation studies have been conducted. The LD50 of GSPE
was found to be greater than 5000 mg/kg when administered once orally via g
astric intubation to fasted male and female albino rats. The LD50 of GSPE w
as found to be greater than 2000 mg/kg when administered once for 24 hr to
the clipped, intact skin of male and female albino rats. In addition, 2000
mg/kg was found to be the no-observed-effect level (NOEL) for systemic toxi
city under the conditions of the study. In a dermal irritation study, GSPE
received a descriptive rating classification of moderately irritating. Exte
nsive chronic studies were also conducted. We have assessed the effects of
chronic administration of 100 mg GSPE/kg/day for twelve months and its effe
ct on seven vital target organs, namely, brain, heart, intestine, kidney, l
iver, lung and spleen, and on serum chemistry changes in male B6C3F1 mice.
Furthermore, the dose-dependent chronic effects of GSPE in female B6C3F1 mi
ce were evaluated. Mice were fed 0, 100, 250 or 500 mg GSPE/kg/day for six
months and the effects of GSPE exposure were examined on brain, duodenum, h
eart, kidney, liver, lung, pancreas and spleen, and on serum chemistry chan
ges in female mice. These acute studies demonstrated that GSPE is safe and
did not cause any detrimental effects in vivo under the conditions investig
ated in this study.